Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...
Discover Veru Inc.'s latest Q1 2025 updates on enobosarm & sabizabulin trials, financials, & strategic pivots in cardiometabolic and inflammation treatment.
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth ...
Share on Pinterest LeoPatrizi/Getty Images Semaglutide is the active ingredient in Wegovy, Ozempic, and Rybelsus. Currently, only Wegovy is approved for weight loss in the United States.
MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage ... patients receiving semaglutide (Wegovy®). The primary endpoint was total lean body mass, and the key ...
MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ ... patients receiving semaglutide (Wegovy®). The primary endpoint was total lean body mass, and the key secondary endpoints ...
One jab, Wegovy, is already available to some people and a second, Mounjaro, will soon be available - although it could be more than a decade before it is fully rolled-out. NHS experts have warned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results